Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD Activity of SNDX-6352 in Subjects With Active cGVHD Who Have Received at Least 2 Lines of Prior Therapy, Including Ibrutinib

Trial Profile

A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD Activity of SNDX-6352 in Subjects With Active cGVHD Who Have Received at Least 2 Lines of Prior Therapy, Including Ibrutinib

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs UCB 6352 (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Sponsors Syndax Pharmaceuticals
  • Most Recent Events

    • 07 Jan 2019 According to a Syndax Pharmaceuticals media release, topline results and a recommended Phase 2 dose and schedule from the Phase 1 trial of SNDX-6352 in patients with chronic graft versus host disease (cGVHD) are expected in the third quarter of 2019.
    • 05 Nov 2018 Status changed from not yet recruiting to recruiting, according to a Syndax Pharmaceuticals media release.
    • 07 Aug 2018 According to a Syndax Pharmaceuticals media release, enrollment in this trial is anticipated to begin by the end of the year, with initial data expected in the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top